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Contrast-Induced Acute Kidney Injury
Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP
Royal Oak, Michigan
Cardiac angiography and coronary/vascular interventions depend on iodinated contrast media and consequently
pose the risk of contrast-induced acute kidney injury (AKI). This is an important complication that accounts for a
significant number of cases of hospital-acquired renal failure, with adverse effects on prognosis and health care
costs. The epidemiology and pathogenesis of contrast-induced AKI, baseline renal function measurement, risk
assessment, identification of high-risk patients, contrast medium use, and preventive strategies are discussed in
this report. An advanced algorithm is suggested for the risk stratification and management of contrast-induced
AKI as it relates to patients undergoing cardiovascular procedures. Contrast-induced AKI is likely to remain a
significant challenge for cardiologists in the future because the patient population is aging and chronic kidney
disease and diabetes are becoming more common. (J Am Coll Cardiol 2008;51:1419–28) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.035p
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iontrast-induced acute kidney injury (AKI) is an important
omplication in the use of iodinated contrast media, which
ccounts for a significant number of cases of hospital-
cquired AKI (1–3). This iatrogenic complication has been
subject of concern to cardiologists in recent years because
f its adverse effect on prognosis and addition to health care
osts. At the same time, many hospitalized patients have
ompromised renal function (4,5), which is the most im-
ortant risk factor for contrast-induced AKI. This report is
argely based upon data from the Contrast-Induced Ne-
hropathy (CIN) Consensus Working Panel, an interna-
ional multidisciplinary group convened to address the
hallenges of contrast-induced AKI whose findings were
ublished in 2006 (6–12).
valuating the Literature
n Contrast-Induced AKI
he CIN Consensus Working Panel comprised 2 radiolo-
ists, 2 cardiologists, and 2 nephrologists practicing in
urope and the U.S. At the first meeting in November
004, the overall scope and strategy for the project were
greed upon and at the second in September 2005, the
orking Panel reviewed and discussed all of the evidence
nd developed a series of consensus statements. A system-
tic search of the literature was undertaken to identify all
eferences relevant to the subject of contrast-induced AKI,
s a result of which 865 potentially relevant studies were
dentified and reviewed. The results of the literature search
ere used to compile reviews covering the epidemiology and
rom the Divisions of Cardiology, Nutrition, and Preventive Medicine, William
eaumont Hospital, Royal Oak, Michigan.T
Manuscript received August 29, 2007; revised manuscript received December 10,
007, accepted December 10, 2007.athogenesis of AKI, baseline renal function measurement,
isk assessment, identification of high-risk patients, contrast
edium use, and preventive strategies (6–12). After review-
ng all of the evidence, a series of consensus statements were
eveloped (Table 1) (13).
pidemiology and Prognostic
mplications of Contrast-Induced AKI
ncidence. The reported incidence of contrast-induced
KI varies widely across the literature, depending on the
atient population and the baseline risk factors. Moreover,
s with any clinical event, the incidence also varies depend-
ng on the criteria by which it is defined. Contrast-induced
KI is typically defined in the recent literature as an
ncrease in serum creatinine (SCr) occurring within the first
4 h after contrast exposure and peaking up to 5 days
fterwards. In most instances, the rise in SCr is expressed
ither in absolute terms (0.5 to 1.0 mg/dl) or as a propor-
ional rise in SCr of 25% or 50% above the baseline value.
he most commonly used definition in clinical trials is a rise
n SCr of 0.5 mg/dl or a 25% increase from the baseline
alue, assessed at 48 h after the procedure. The European
ociety of Urogenital Radiology defines contrast-induced
KI as impairment in renal function (an increase in SCr by
0.5 mg/dl or 25% within 3 days after intravascular
dministration of contrast medium, without an alternative
tiology) (14). The Acute Kidney Injury Network definition
s a rise in SCr 0.3 mg/dl with oliguria, which is
ompatible with previous definitions and may be a new
tandard to follow.
The best indication of the healthcare impact of contrast-
nduced AKI comes from large studies of hospital patients.
he frequency of contrast-induced AKI has decreased over
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Contrast-Induced AKI April 15, 2008:1419–28the past decade from a general
incidence of 15% to 7% of
patients (15). This is due to a
greater awareness of the prob-
lem, better risk prevention mea-
sures, and improved iodinated
contrast media with less renal
toxicity. However, many cases of
contrast-induced AKI continue
to occur because of the ever-
increasing numbers of proce-
dures requiring contrast. Nash
et al. (3) reported that radio-
graphic contrast media were the
third most common cause of
hospital-acquired renal failure
(after decreased renal perfusion
and nephrotoxic medications)
and were responsible for 11% of
cases.
It has been recognized for some
time that the risk of death is in-
creased in patients developing
contrast-induced AKI (16–20).
In a large retrospective study of
ver 16,000 hospitalized patients undergoing procedures
equiring iodinated contrast, a total of 183 subjects devel-
ped contrast-induced AKI (defined as a 25% increase in
Cr) (21). The risk of death during hospitalization was 34%
n subjects who developed contrast-induced AKI compared
ith 7% in matched control subjects who had received
ontrast medium but did not develop contrast-induced AKI.
ven after adjusting for comorbid disease, patients with
ontrast-induced AKI had a 5.5-fold increased risk of death
21). The high risk of in-hospital death associated with
ontrast-induced AKI was also documented in a retrospec-
ive analysis of 7,586 patients, of whom 3.3% developed
ontrast-induced AKI after exposure to contrast medium.
mong the patients who developed contrast-induced AKI,
he in-hospital death rate was 22% compared with only
.4% in patients who did not develop AKI (22). The
ortality rates at 1 year after development of contrast-
nduced AKI (12.1%) and at 5 years (44.6%) were higher
ompared with rates of 3.7% and 14.5%, respectively, in
atients who did not develop contrast-induced AKI (p 
.001), indicating that the increased risk of death persisted
n the long term. A further study confirmed the high
ortality in patients who develop contrast-induced AKI,
specially in those who require dialysis: the hospital mor-
ality was 7.1% in contrast-induced AKI patients and 35.7%
n patients who required dialysis. By 2 years, the mortality
ate in patients who required dialysis was 81.2% (17).
ontrast-induced AKI (defined as an increase 25% in
Cr) occurred in 37% of 439 patients with renal impairment
baseline SCr 1.8 mg/dl) undergoing percutaneous coro-
Abbreviations
and Acronyms
AKI  acute kidney injury
CIN  contrast-induced
nephropathy
CKD  chronic kidney
disease
CK-MB  creatine kinase-
myocardial band
Cr  creatinine
DM  diabetes mellitus
eGFR  estimated
glomerular filtration rate
HOCM  high-osmolal
contrast media
IOCM  iso-osmolal
contrast media
LOCM  low-osmolal
contrast media
MI  myocardial infarction
NAC  N-acetylcysteine
PCI  percutaneous
coronary interventionary intervention (PCI) (23). In this group, the hospital lortality rate was 14.9% compared with 4.9% in patients
ithout contrast-induced AKI (p 0.001). The cumulative
-year mortality rates were 37.7% and 19.4%, respectively.
he 1-year mortality was 45.2% for patients with contrast-
nduced AKI requiring dialysis and 35.4% for those with
ontrast-induced AKI not requiring dialysis (23). In pa-
ients undergoing primary PCI for myocardial infarction
MI), short- and long-term mortality rates were also signif-
cantly higher in those who developed contrast-induced
KI (24,25). Furthermore, in this group, it has been shown
hat contrast-induced AKI is an independent predictor of
ortality (26).
mpact of contrast-induced AKI on clinical course and
utcome. As well as an increased risk of death, contrast-
nduced AKI is also associated with other adverse outcomes
ncluding late cardiovascular events after PCI. In 1 registry
f 5,967 PCI patients, the development of contrast-induced
KI was associated with an increased incidence of MI and
arget vessel revascularization at 1 year (26). Another large
CI study documented the link between contrast-induced
KI, post-procedural increases in creatine kinase-
yocardial band (CK-MB) subfraction, and the risk of late
ardiovascular events (27). In a group of 5,397 patients, a
ost-procedural rise in SCr was a more powerful predictor
f late mortality than CK-MB. Creatinine increases were
ssociated with a 16% rate of death or MI at 1 year, rising
o 26.3% when CK-MB levels were also elevated after the
rocedure (27).
More in-hospital events such as bypass surgery, bleeding
equiring transfusion, and vascular complications were
bserved in patients who developed contrast-induced
KI, both in those with previous renal dysfunction and
hose with previously normal renal function. At 1 year,
he cumulative rate of major adverse cardiac events was
ignificantly higher in patients who had developed
ontrast-induced AKI (p  0.0001 for patients with and
ithout chronic kidney disease [CKD]) (28). However,
thers have observed no difference in the rates of MI and
arget vessel revascularization in patients with contrast-
nduced AKI (23).
The development of contrast-induced AKI has also been
ssociated with an increased hospital stay. In 1 series, the
ost-procedure hospital stay was longer for patients who
eveloped contrast-induced AKI, regardless of baseline
enal function (28). In a series of 200 patients undergoing
CI for acute MI, patients who developed contrast-induced
KI had a longer hospital stay, a more complicated clinical
ourse, and a significantly increased risk of death compared
ith those without contrast-induced AKI (25).
conomic impact. A recent economic analysis of the direct
osts associated with contrast-induced AKI showed that the
verage additional cost was $10,345 for the hospital stay and
11,812 to 1 year (29). The incidence and outcome data
ere determined from studies identified through a system-
tic literature search and combined with unit costs from the
iterature in a decision analytic model. The major driver of
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April 15, 2008:1419–28 Contrast-Induced AKIhe increased costs associated with contrast-induced AKI
as the cost of the longer initial hospital stay.
isk of contrast-induced AKI requiring dialysis. While
ost cases of contrast-induced AKI reflect mild transient
mpairment of renal function, dialysis is needed in a small
roportion of patients. The need for dialysis after contrast-
nduced AKI varies according to patients’ underlying risks at
he time of contrast administration but is generally less than
% (17,30,31), although it was considerably higher in some
lder studies with high-osmolal contrast media (HOCM)
32,33). In contemporary studies, contrast-induced AKI
equiring dialysis developed in almost 4% of patients with
nderlying renal impairment (34) and 3% of patients un-
ergoing primary PCI for acute coronary syndromes (25).
lthough contrast-induced AKI requiring dialysis is rela-
ively rare, the impact on patient prognosis is considerable,
ith high hospital and 1-year mortality rates (17,23).
athophysiology of Contrast-Induced AKI
hronic kidney disease is both necessary and sufficient for
he development of contrast-induced AKI. In patients with
KD, identified by an estimated glomerular filtration rate
eGFR) 60 ml/min/1.73 m2 (which roughly corresponds
n the elderly to a SCr 1.0 mg/dl in a woman and 1.3
onsensus Statements
Table 1 Consensus Statements
Consensus Statement 1
Contrast-induced AKI is a common and potentially serious complication after the ad
Consensus Statement 2
The risk of contrast-induced AKI is elevated and of clinical importance in patients wi
eGFR rate 60 ml/min/1.73 m2.
Consensus Statement 3
When serum creatinine or eGFR is unavailable, then a survey may be used to identif
Consensus Statement 4
In the setting of emergency procedures, where the benefit of very early imaging outw
creatinine or eGFR.
Consensus Statement 5
The presence of multiple contrast-induced AKI risk factors in the same patient or hig
(15%) acute renal failure requiring dialysis after contrast exposure.
Consensus Statement 6
In patients at increased risk for contrast-induced AKI undergoing intra-arterial admin
AKI than low-osmolality agents. Current evidence suggests that for intra-arterial a
diabetes mellitus, nonionic, iso-osmolar contrast is associated with the lowest risk
Consensus Statement 7
Higher contrast volumes (100 ml) are associated with higher rates of contrast-indu
in very high-risk patients can cause contrast-induced AKI and acute renal failure r
Consensus Statement 8
Intra-arterial administration of iodinated contrast appears to pose a greater risk of c
Consensus Statement 9
Adequate intravenous volume expansion with isotonic crystalloid (1.0–1.5 ml/kg/h)
probability of contrast-induced AKI in patients at risk. The data on oral as opposed
insufficient.
Consensus Statement 10
No adjunctive medical or mechanical treatment has been proven to be efficacious re
hemofiltration has not been validated as an effective strategy.
KI  acute kidney injury; eGFR  estimated glomerular filtration.
Adapted from McCullough et al. (13).g/dl in a man), there is a considerable loss of nephron lnits, and the residual renal function is vulnerable to
eclines with renal insults (iodinated contrast, cardiopulmo-
ary bypass, renal-toxic medications, and so on). Thus, the
athophysiology of contrast-induced AKI assumes baseline
educed nephron number, with superimposed acute vaso-
onstriction caused by the release of adenosine, endothelin,
nd other renal vasoconstrictors triggered by iodinated
ontrast. After a very brief increase in renal blood flow, via
he above mechanisms, there is an overall 50% sustained
eduction in renal blood flow lasting for several hours
Fig. 1). There is concentration of iodinated contrast in the
enal tubules and collecting ducts, resulting in a persistent
ephrogram on fluoroscopy. This stasis of contrast in the
idney allows for direct cellular injury and death to renal
ubular cells. The degree of cytotoxicity to renal tubular cells
s directly related to the length of exposure those cells have
o iodinated contrast, hence, the importance of high urinary
ow rates before, during, and after contrast procedures. The
ustained reduction in renal blood flow to the outer medulla
eads to medullary hypoxia, ischemic injury, and death of
enal tubular cells. By these 2 mechanisms, it is believed that
ther organ injury processes including oxidative stress and
nflammation may play a further role. Any superimposed
nsult such as sustained hypotension in the catheterization
ation of contrast media in patients at risk for acute renal injury.
nic kidney disease (particularly when diabetes is also present), recognized by an
nts at higher risk for contrast-induced AKI than the general population.
the risk of waiting, the procedure can be performed without knowledge of serum
clinical scenarios can create a very high risk (50%) for contrast-induced AKI and
on of contrast, ionic high-osmolality agents pose a greater risk for contrast-induced
tration in high-risk patients with chronic kidney disease, particularly those with
ntrast-induced AKI.
KI in patients at risk. However, even small (30 ml) volumes of iodinated contrast
g dialysis, suggesting the absence of a threshold effect.
t-induced AKI above that with intravenous administration.
2 h before the procedure and continued for 6–24 h afterwards can lessen the
ravenous volume expansion as a contrast-induced AKI prevention measure are
g the risk of AKI after exposure to iodinated contrast. Prophylactic hemodialysis orministr
th chro
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Contrast-Induced AKI April 15, 2008:1419–28atheter exchanges or the use of intra-aortic balloon coun-
erpulsation, or a bleeding complication can amplify the
njury processes occurring in the kidney. A detailed review
f pathophysiology is outside the scope of this report, and
he reader is referred to a published review for further
nformation (9).
he Role of Baseline Renal Function Screening
irtually every report describing risk factors for contrast-
nduced AKI lists abnormal baseline SCr, low GFR, or
KD as risk factors. Almost every multivariate analysis has
hown that CKD is an independent risk predictor for
ontrast-induced AKI (1,15,22,30,34,35). The risk of
ontrast-induced AKI is increased in patients with an eGFR
60 ml/min/1.73 m2 (stage 3 to 5 CKD), and special
recautions should be taken in these patients. These state-
ents apply to stable renal function. In critically ill patients,
enal function may be dynamic and compromised (due to
ardiogenic shock, heart failure, drug-induced injury, and so
n), making the risk state greater, and thus, clinical judge-
ent must be applied to the assessment of baseline renal
unction.
easurement of baseline renal function. It is important
o assess renal function before administration of contrast
edium to ensure that appropriate steps are taken to reduce
he risk. Since SCr alone does not provide a reliable measure
f renal function, the National Kidney Foundation Kidney
isease Outcome Quality Initiative recommends that clini-
Figure 1 Postulated Pathophysiology of Contrast-Induced AKI
In the presence of a reduced nephron mass, the remaining nephrons are vul-
nerable to injury. Iodinated contrast, after causing a brief (minutes) period of
vasodilation, causes sustained (hours to days) intrarenal vasoconstriction and
ischemic injury. The ischemic injury sets off a cascade of events largely driven
by oxidative injury causing death of renal tubular cells. If a sufficient mass of
nephron units are affected, then a recognizable rise in serum creatinine will
occur.ians should use an eGFR calculated from the SCr as an hndex of renal function rather than using SCr (36) in stable
atients.
se of surveys/questionnaires. It is highly desirable to
ave an eGFR value available in order to assess the risk of
ontrast-induced AKI, but this may be impractical in some
ircumstances, especially in outpatient cardiac computed
omography angiography. Where renal function data are
navailable, a simple survey or questionnaire may be used
o identify outpatients at higher risk for AKI in whom
ppropriate precautions should be taken (37–39). A brief
-item survey inquires on the following: 1) history of renal
isease; 2) prior renal surgery; 3) proteinuria; 4) diabetes
ellitus (DM); 5) hypertension; 6) gout; and 7) use of
ephrotoxic drugs (nonsteroidal anti-inflammatory agents,
nd so on). The majority of patients with CKD would have
or more positive responses to these questions. For patients
ndergoing scheduled catheterization procedures, the SCr
hould be available before contrast is given.
mergency situations. In the setting of emergency proce-
ures, where the benefit of very early imaging outweighs the
isk of waiting for the results of a blood test, it may be
ecessary to proceed without SCr assessment or GFR
stimation (8). This is particularly relevant to patients
ndergoing emergency catheterization or primary PCI. It is
uggested that a baseline blood sample is taken before the
mergency procedure to enable monitoring afterwards even
f the initial result is not immediately known. However,
hen possible, an indication should be obtained of the
ikelihood that the patient has impaired renal function that
ay increase the risk of AKI, to enable suitable precautions
o be taken.
isk Markers for AKI After Iodinated Contrast
he term “risk marker” as opposed to “risk factor” is
referred since many of the indicators of risk for contrast-
nduced AKI are nonmodifiable and are not necessarily
ausative (6). Baseline renal filtration function is a surrogate
or reduced nephron mass and renal parenchymal function
9). As indicated in the preceding text, because CKD
mplies a loss of nephron units, the risk of contrast-induced
KI is increased in patients with an eGFR 60 ml/min/
.73 m2, and special precautions should be taken in these
atients (9).
Other risk markers include DM (26,28), volume deple-
ion (40), nephrotoxic drugs, hemodynamic instability
27,41), and other comorbidities. Importantly, DM is nei-
her necessary nor sufficient as a determinant for contrast-
nduced AKI. However, DM appears to act as a risk
ultiplier, meaning that in a patient with CKD it amplifies
he risk of contrast-induced AKI (Fig. 2). Several large
eries of PCI patients have shown an association between
ontrast-induced AKI and indicators of hemodynamic in-
tability such as periprocedural hypotension and use of an
ntra-aortic balloon pump (26,28). It is not surprising that
ypotension increases the risk of contrast-induced AKI
s
s
p
c
c
f
h
o
p
t
t
c
w
c

H
M
c
s
s
o
r
c
e
r
f
“
a
a
p
p
B
r
g
i
c
i
c
C
C
p
b
c
p
e
c
m
a
4
b
1
8
a
i
o
w
o
i
t
o
s
o
i
i
c
l
i
h
v
c
(
i
t
l
s
l
s
p
h
1423JACC Vol. 51, No. 15, 2008 McCullough
April 15, 2008:1419–28 Contrast-Induced AKIince it increases the likelihood of renal ischemia and is a
ignificant risk factor for acute renal failure in acutely ill
atients. Anemia has also been reported as a predictor of
ontrast-induced AKI (42).
The effect of risk factors is additive, and the likelihood of
ontrast-induced AKI rises sharply as the number of risk
actors increases (17,41). A similar pattern of additive risk
as been documented for AKI requiring dialysis (30).
The additive nature of risk has allowed the development
f prognostic scoring schemes (15,41), but since none of the
ublished schemes has been adequately studied or prospec-
ively validated in different populations, it is not appropriate
o recommend routine use of any particular risk scoring in
linical practice. However, the concept is that in a patient
ith CKD, DM, and other comorbidities, predicted risks of
ontrast-induced AKI and emergency dialysis can approach
50% and 15%, respectively.
igh-Risk Situations and Procedures
any clinical situations may arise in which the risk of
ontrast-induced AKI is increased, with the most common
cenario in the catheterization laboratory being cardiogenic
hock (6). While in general, the benefits of revascularization
utweigh the risks of the procedure, in the setting of shock
equiring the placement of an intra-aortic balloon pump,
onsiderably higher rates of contrast-induced AKI can be
xpected. A common scenario in complicated patients is
epeated exposure to iodinated contrast over a period of a
ew days. While there are no studies on the ideal interim
Figure 2 Risk of Contrast-Induced AKI According to
Baseline Renal Function (eGFR or CrCl ml/min)
Contrast-induced acute kidney injury (AKI) was defined as serum creatinine
increase of 25% and/or 0.5 mg/dl and is shown separately for patients with
(solid circles) and without (open circles) diabetes. CrCl  creatinine clear-
ance; eGFR  estimated glomerular filtration rate. Data adapted from
McCullough et al. (12).rest” period for the kidneys, the general principal is that if tdditional contrast is given in the setting of AKI, outcomes
re likely to worsen. Most clinical trials have used an interim
eriod of 10 days from a prior procedure to be sure the
atient has not incurred AKI from the first procedure.
ecause of the added insult of cardiopulmonary bypass, the
isk of contrast-induced AKI in patients undergoing emer-
ency coronary artery bypass surgery after angiography is
ncreased. Finally, the published literature on the risk of
ontrast-induced AKI in heart or renal transplant recipients
s inconsistent, and clinicians should be conservative and
onsider them at high risk (6).
ontrast Medium Use
hoice of contrast medium. Iodinated contrast media
ackages iodine atoms, which are radiopaque, on carbon-
ased molecules, which are water soluble. Contrast media is
lassified according to osmolality, which reflects the total
article concentration of the solution (the number of mol-
cules dissolved in a specific volume). Contrast media can be
ategorized according to osmolality (HOCM 2,000
Osm/kg, low-osmolal [LOCM] 600 to 800 mOsm/kg,
nd isosmolal [IOCM] 290 mOsm/kg) (7). Over the past
0 years, the osmolalities of available contrast media have
een gradually decreased to physiological levels. In the
950s, only HOCM (e.g., diatrizoate) with osmolality 5 to
times that of plasma were used. In the 1980s, LOCM
gents such as iohexol, iopamidol, and ioxaglate were
ntroduced, having osmolality 2 to 3 times greater than that
f plasma. In the 1990s, iso-osmolar nonionic iodixanol
ith the same physiological osmolality as blood was devel-
ped. Red blood cell deformation, systemic vasodilation,
ntrarenal vasoconstriction, as well as direct renal tubular
oxicity are all more common in contrast agents with
smolality greater than that of blood. In a meta-analysis of
tudies before 1992, the pooled odds ratio for the incidence
f contrast-induced AKI events (rise in SCr of 0.5 mg/dl
n 25 trials was 0.61), 95% confidence interval 0.48 to 0.77,
ndicating a significant reduction in risk with LOCM
ompared with that seen with HOCM (43). Studies pub-
ished since this meta-analysis generally support these find-
ngs (44). Most studies comparing different LOCM agents
ave been small trials that have not shown clinically relevant
ariation within this class (7).
Iodixanol has been shown to have the lowest risk for
ontrast-induced AKI in patients with CKD and DM
45,46). In a pooled analysis of 16 head-to-head, random-
zed trials (2,727 patients) of intra-arterial contrast medium,
he incidence of contrast-induced AKI was significantly
ower with iodixanol than with LOCM (Fig. 3) (47). A
ystematic review by Solomon (48) also demonstrated the
owest risk of contrast-induced AKI with iodixanol. This
tudy included a total of 17 prospective clinical trials (1,365
atients), but only 2 of these trials were randomized
ead-to-head comparisons of iodixanol versus LOCM, and
he other data came from the placebo arms of 13 trials of
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Contrast-Induced AKI April 15, 2008:1419–28reventive strategies for contrast-induced AKI and the
OCM arms of 2 trials comparing LOCM and HOCM.
inally, a meta-analysis of the renal tolerability of another
OCM, iotrolan 280 (not approved for intravascular use),
rovides further evidence that IOCM are associated with a
ower risk of contrast-induced AKI (49). In this analysis of
4 double-blind studies, it was found that iotrolan had less
ffect on renal function that the LOCM with which it was
ompared (iopamidol, iohexol, iopromide).
Several more clinical trials have been published since the
iterature search undertaken by the CIN Consensus Work-
ng Panel supporting the view that iodixanol is the least
ephrotoxic agent available for intravascular use. A Korean
ead-to-head randomized trial showed a significantly lower
ate of contrast-induced AKI with iodixanol compared with
OCM in high-risk patients undergoing coronary angiog-
aphy (50). However, in recent trials of lower-risk patients
ndergoing computed tomography, the rates of contrast-
nduced AKI were similar with iodixanol and LOCM after
ntravenous administration for computed tomography (51)
r intracoronary administration (52). In both trials, the
iagnosis of contrast-induced AKI depended on a single
onstandardized SCr measurement after the procedure,
ielding low event rates in insufficient power to find differ-
nces between the agents.
Finally, the American College of Cardiology/American
eart Association guidelines for the management of acute
oronary syndromes patients with CKD listed the use of
OCM as a class I, Level of Evidence: A recommendation
53). The National Kidney Foundation Kidney Disease
utcome Quality Initiative guidelines have also recom-
Figure 3 Rates of Contrast-Induced AKI in a Meta-
Analysis of 16 Trials of Iso-Osmolar Iodixanol
Relative risk reductions (RRRs) are for iso-osmolar (IOCM) compared with low-
osmolar contrast media (LOCM). CKD  baseline chronic kidney disease
defined as an estimated creatinine clearance 60 ml/min; DM  diabetes
mellitus. Data adapted from McCullough et al. (47).ended use of IOCM in renal dialysis patients to minimize the chances of volume overload and complications before
he next dialysis session (7).
olume of contrast. Numerous studies have shown that
he volume of contrast medium is a risk factor for contrast-
nduced AKI. The mean contrast volume is higher in
atients with contrast-induced AKI, and most multivariate
nalyses have shown that contrast volume is an independent
redictor of contrast-induced AKI (17,26,30,41). However,
ven small volumes (30 ml) of contrast medium can have
dverse effects on renal function in patients at particularly
igh risk (54). As a general rule, the volume of contrast
eceived should not exceed twice the baseline level of eGFR
n milliliters (55). This means for patients with significant
KD, a diagnostic catheterization should plan to use 30
l of contrast, and if followed by PCI then100 ml should
e a reasonable goal.
ntra-arterial versus intravenous administration. A number of
tudies have provided circumstantial evidence that the risk of
ontrast-induced AKI may be higher after intra-arterial
han after intravenous injection (56,57). However, none of
hese studies provides an insight into the significance of the
oute of administration for contrast-induced AKI risk in
ontemporary practice, especially with regard to computed
omography studies, when a comparatively large volume of
ontrast medium may be given as a compact intravenous
olus rather than an infusion. Current practice of cardiac
omputed tomography angiography calls for contrast loads
f 80 to 120 ml. At these levels, in a high-risk patient for
ontrast-induced AKI, a single procedure with diagnostic
atheterization and PCI if warranted with operator-
ontrolled minimization of contrast exposure appears to
e a more reasonable strategy than cardiac computed
omography angiography followed by angiography.
ther Strategies for Reducing Risk
ithholding nephrotoxic drugs. While there are no with-
rawal studies in this area, it is reasonable practice to hold
onsteroidal anti-inflammatory drugs, calcineurin inhibi-
ors, high-dose loop diuretics, aminoglycosides, and other
ephrotoxic agents if possible for several days before con-
rast exposure. It is routine practice to hold metformin
efore all contrast procedures not because metformin itself
s nephrotoxic, but because in the setting of AKI if met-
ormin is continued, lactic acidosis can develop leading to
ystemic complications and death. In the setting of acciden-
al administration of metformin in a patient with AKI, the
etformin can be cleared from the body with dialysis. As a
eneral rule, metformin should not be restarted until the
linician is confident that the patient has not incurred AKI.
inally, there is controversy over whether drugs that block
he renin angiotensin system should be held or continued
or contrast procedures. Clinical trials of these agents to
revent contrast-induced AKI have not demonstrated harm,
ith 1 larger trial of an angiotensin-II receptor blocker yet
o report, so at the time of this writing it is reasonable to
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April 15, 2008:1419–28 Contrast-Induced AKIontinue these drugs for their chronic cardiovascular and
enal indications.
olume expansion. Volume expansion and treatment of
ehydration has a well-established role in prevention of
ontrast-induced AKI, although few studies address this
heme directly. There are limited data on the most appro-
riate choice of intravenous fluid, but the evidence indicates
hat isotonic crystalloid (saline or bicarbonate solution) is
robably more effective than half-normal saline (58). Addi-
ional confirmatory trials with sodium bicarbonate (59) are
eeded because the largest trial to date showed no benefit of
odium bicarbonate over normal saline (60).
There is also no clear evidence to guide the choice of the
ptimal rate and duration of infusion. However, good urine
utput (150 ml/h) in the 6 h after the procedure has been
ssociated with reduced rates of AKI in 1 study (61). Since
ot all of intravenously administered isotonic crystalloid
emains in the vascular space, in order to achieve a urine
ow rate of at least 150 ml/h, 1.0 to 1.5 ml/kg/min of
ntravenous fluid has to be administered for 3 to 12 h before
nd 6 to 12 h after contrast exposure. Oral volume expan-
ion may have some benefit, but there is not enough
vidence to show that it is as effective as intravenous volume
xpansion (62).
ialysis and hemofiltration. Contrast medium is removed
y dialysis, but there is no clinical evidence that prophylactic
ialysis reduces the risk of AKI, even when carried out
ithin 1 h or simultaneously with contrast administration.
emofiltration, however, performed 6 h before and 12 to
8 h after contrast deserves consideration given reports of
educed mortality and need for hemodialysis in the post-
rocedure period in very high-risk patients (SCr 3.0 to 4.0
g/dl, eGFR 15 to 20 ml/min/1.73 m2) (63,64). Hemofil-
ration works to ensure adequate intravascular volume,
educes uremic toxins that may worsen AKI, and provides
tability to the high-risk patient after the procedure, reduc-
ng the risks of oliguria, volume overload, and electrolyte
mbalance, which are associated with short-term mortality.
nder the direction of a nephrologist, a double lumen
atheter is placed in a jugular or femoral vein for blood
ithdrawal and reinfusion and connected with an extracor-
oreal circuit. Blood is driven through the circuit by means
f a peristaltic pump (e.g., Prisma hemofiltration pump,
ambro, Inc., Lakewood, Colorado) at a rate of 100
l/min. Isotonic replacement fluid (post-dilution hemofil-
ration) is set at a rate of 1,000 ml/h and is matched with the
ate of ultrafiltrate production so that no net fluid loss
ccurs. The cardiologist should be aware that hemofiltration
alls for a 5,000-IU heparin bolus before initiation followed
y a continuous heparin infusion of 500 to 1,000 IU/h
hrough the inflow side of the catheter. At the time of the
ardiac procedure, the hemofiltration treatment should be
topped, and the circuit temporarily filled with a saline
olution and short circuited to exclude the patient without
nterruption of the flow. Immediately after the procedure,
he hemofiltration should be restarted. This approach should be considered only in the very highest-risk patient in
onjunction with nephrology consultation and dialysis
lanning.
harmacologic strategies. There are currently no ap-
roved pharmacologic agents for the prevention of AKI.
ith iodinated contrast, the pharmacologic agents tested
n small trials that deserve further evaluation include the
ntioxidants ascorbic acid and N-acetylcysteine (NAC),
tatins, aminophylline/theophylline, and prostaglandin
1 (10).
Of these agents, only ascorbic acid has been tested in a
ulticenter, blinded, placebo-controlled trial (n  231) and
een shown to reduce rates of contrast-induced AKI. The
ose of ascorbic acid (vitamin C over the counter) used in
his trial was 3 g orally the night before and 2 g orally twice
day after the procedure (65).
Although popular, NAC has not been consistently shown
o be effective. Nine published meta-analyses have been
ublished (10), all documenting the significant hetero-
eneity between studies and pooled odds ratios for NAC
pproaching unity. Importantly, only in those trials where
AC reduced SCr below baseline values because of de-
reased skeletal muscle production did renal injury rates
ppear to be reduced. Thus, NAC appears to falsely lower
r and not fundamentally protect against AKI. However,
AC as an antioxidant has been shown to lower rates of
KI and mortality after primary PCI in 1 trial (66). The
ecently published REMEDIAL (Renal Insufficiency Fol-
owing Contrast Media Administration) trial suggested that
he use of volume supplementation with sodium bicarbonate
ogether with NAC was more effective than NAC alone in
educing the risk of AKI (67). Dosing of NAC has varied in
he trials; however, the most successful approach has been
ith 1,200 mg orally twice a day on the day before and after
he procedure.
Fenoldopam, dopamine, calcium-channel blockers, atrial
atriuretic peptide, and L-arginine have not been shown to
e effective in the prevention of contrast-induced AKI.
urosemide, mannitol, and an endothelin receptor antago-
ist are potentially detrimental (10).
In general, cardiovascular patients undergoing procedures
ith iodinated contrast have either high risk for atheroscle-
osis or have the anatomic presence of disease. Therefore,
he vast majority of patients should be on statin therapy with
common low-density lipoprotein cholesterol target of70
g/dl. Several studies have demonstrated that patients
ontinued on statins during cardiovascular procedures in-
luding PCI and coronary artery bypass grafting have lower
ates of AKI (68). All small randomized trials published to
ate support this concept as well (69,70). Preservation of
ndothelial function at the level of the glomerulus and
eductions in systemic inflammatory factors are postulated
echanisms by which statins may have renoprotective
ffects. Thus, statins should be a standard of care for
atients undergoing these procedures for a variety of rea-
ons, and should be started at baseline and continued over
t
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Contrast-Induced AKI April 15, 2008:1419–28he long-term course of care provided they are well tolerated
without skeletal muscle or liver adverse effects).
An integrated advanced algorithm for the management of
ontrast-induced AKI is presented in Figure 4. It should be
oted that there are no approved pharmaceutical agents for
he prevention of this complication; thus, the practitioner
hould be cautious with the use of any of the drugs
uggested. Importantly, all patients at risk for contrast-
nduced AKI should have follow-up Cr and electrolyte
onitoring daily while in hospital, and then at 48 to 96 h
fter discharge. Rehospitalization is reasonable for uremic
ymptoms, hyperkalemia, and volume overload in the set-
ing of AKI.
ovel Biomarkers
s discussed in the preceding text, SCr is both an indirect
nd insensitive marker of baseline kidney function and of
KI. Thus, there is considerable interest in developing
lood and urine biomarkers for AKI analogous to troponin
or acute MI. Neutrophil gelatinase-associated lipocalin, a
ember of the lipocalin family, is readily excreted and
etected in urine, due to its small molecular size (25 kDa)
nd resistance to degradation. Neutrophil gelatinase-
ssociated lipocalin is highly accumulated in the human kidney
ortical tubules, blood, and urine after nephrotoxic and isch-
mic injuries such as exposure to iodinated contrast. Thus,
hole blood neutrophil gelatinase-associated lipocalin might
epresent an early, sensitive biomarker for AKI being devel-
ped for point-of-care use in the catheterization laboratory
Figure 4 Advanced Algorithm for Management of Patients Rec
ACS  acute coronary syndromes; bid  twice daily; Cr  creatinine; DM  diabe
NAC  N-acetylcysteine; NSAIDs  nonsteroidal anti-inflammatory drugs; PGE 171,72). Finally, Cystatin C is a serum protein that is filtered
ut of the blood by the kidneys and that serves as a measure
f kidney function. Cystatin C is produced steadily by all
ypes of nucleated cells in the body. Its low molecular mass
llows it to be freely filtered by the glomerular membrane in
he kidney. Its concentration in blood correlates with the
lomerular filtration rate. The levels of Cystatin C are
ndependent of weight and height, muscle mass, age, and
ender. Measurements can be made and interpreted from a
ingle random sample. Cystatin C is a better marker of the
lomerular filtration rate and kidney function than Cr and is
leared for use by the U.S. Food and Drug Administration.
t is expected that this marker will replace SCr in the future
s the blood marker of renal filtration function.
uture Preventive Approaches
ecause contrast-induced AKI has a timed injury to the
idney, it is one of the most amenable forms of AKI for
linical trials. Future approaches include large planned
tudies of oral and intravenous antioxidants (including a
otent oral antioxidant, deferiprone), intrarenal infusions of
enal vasodilators using flow directed catheters, forced
ydration with marked elevations of urine output to reduce
he transit time of iodinated contrast in the renal tubules,
ystemic cooling, and novel, hopefully less toxic, forms of
adio-opaque contrast agents. Another novel approach may
nvolve coronary sinus withdrawal of blood and contrast
fter intracoronary injection, thus reducing the volume of
ontrast delivered downstream to the kidneys (73,74). If
Iodinated Contrast Media
llitus; IV  intravenous;
glandin E ; po  by mouth; other abbreviations as in Figure 2.eiving
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April 15, 2008:1419–28 Contrast-Induced AKIardiovascular procedures could be performed with no risk
f AKI, it is expected that major adverse cardiac and
edical complications could be appreciably reduced. This is
xactly the hypothesis encouraged in future, large-scale
utcomes trials of contrast-induced AKI prevention.
onclusions
he consensus statements summarized in this chapter can
elp guide the management of patients receiving iodinated
ontrast medium in the cardiac and vascular imaging labo-
atory. Multicenter, large-scale randomized trials of preven-
ive strategies are needed to evaluate changes in renal
unction and meaningful clinical outcomes. Future, non-
oxic imaging agents are needed to manage the ever-
ncreasing numbers of vulnerable patients undergoing car-
iac procedures.
eprint requests and correspondence: Dr. Peter A. McCullough,
ivisions of Cardiology, Nutrition, and Preventive Medicine,
illiam Beaumont Hospital, 4949 Coolidge Highway, Royal
ak, Michigan 48073. E-mail: pmc975@yahoo.com.
EFERENCES
1. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit
Care Clin 2005;21:261–80.
2. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR
Am J Roentgenol 2004;183:1673–89.
3. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J
Kidney Dis 2002;39:930–6.
4. Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and
economic burden of renal impairment in cardiac intensive care. Intern
Med J 2006;36:185–92.
5. Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in
critically ill patients by severity of kidney dysfunction: a population-
based assessment. Am J Kidney Dis 2006;48:402–9.
6. Becker CR, Davidson C, Lameire N, et al. High-risk situations and
procedures. Am J Cardiol 2006;98:37K–41K.
7. Davidson C, Stacul F, McCullough PA, et al. Contrast medium use.
Am J Cardiol 2006;98:42K–58K.
8. Lameire N, Adam A, Becker CR, et al. Baseline renal function
screening. Am J Cardiol 2006;98:21K–6K.
9. McCullough PA, Adam A, Becker CR, et al. Risk prediction of
contrast-induced nephropathy. Am J Cardiol 2006;98:27K–36K.
0. Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of
contrast-induced nephropathy. Am J Cardiol 2006;98:59K–77K.
1. Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-
induced nephropathy. Am J Cardiol 2006;98:14K–20K.
2. McCullough PA, Adam A, Becker CR, et al. Epidemiology and
prognostic implications of contrast-induced nephropathy. Am J Car-
diol 2006;98:5K–13K.
3. McCullough PA, Stacul F, Davidson C, et al. Overview. Am J Cardiol
2006;98:2K–4K.
4. Thomsen HS. Guidelines for contrast media from the European
Society of Urogenital Radiology. AJR Am J Roentgenol 2003;181:
1463–71.
5. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephrop-
athy after percutaneous coronary intervention and a method for risk
stratification. Am J Cardiol 2004;93:1515–9.
6. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal
insufficiency: a prospective study. Am J Med 1983;74:243–8.
7. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after
coronary intervention: incidence, risk factors, and relationship to
mortality. Am J Med 1997;103:368–75.8. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the
incidence and outcome of contrast-induced nephropathy after percu-
taneous coronary intervention. J Invasive Cardiol 2003;15:18–22.
9. Polena S, Yang S, Alam R, et al. Nephropathy in critically ill patients
without preexisting renal disease. Proc West Pharmacol Soc 2005;48:
134–5.
0. Haveman JW, Gansevoort RT, Bongaerts AH, et al. Low incidence of
nephropathy in surgical ICU patients receiving intravenous contrast: a
retrospective analysis. Intensive Care Med 2006;32:1199–205.
1. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on
mortality. A cohort analysis. JAMA 1996;275:1489–94.
2. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic
importance of acute renal failure after percutaneous coronary interven-
tion. Circulation 2002;105:2259–64.
3. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications
of further renal function deterioration within 48 h of interventional
coronary procedures in patients with pre-existent chronic renal insuf-
ficiency. J Am Coll Cardiol 2000;36:1542–8.
4. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insuffi-
ciency in patients undergoing primary angioplasty for acute myocardial
infarction. Circulation 2003;108:2769–75.
5. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy
in patients undergoing primary angioplasty for acute myocardial
infarction. J Am Coll Cardiol 2004;44:1780–5.
6. Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary
intervention-associated nephropathy foreshadows increased risk of late
adverse events in patients with normal baseline serum creatinine.
Catheter Cardiovasc Interv 2003;59:338–43.
7. Lindsay J, Canos DA, Apple S, et al. Causes of acute renal dysfunction
after percutaneous coronary intervention and comparison of late
mortality rates with postprocedure rise of creatine kinase-MB versus
rise of serum creatinine. Am J Cardiol 2004;94:786–9.
8. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephrop-
athy after percutaneous coronary interventions in relation to chronic
kidney disease and hemodynamic variables. Am J Cardiol 2005;95:
13–9.
9. Subramanian S, Tumlin J, Bapat B, et al. Economic burden of
contrast-induced nephropathy: implications for prevention strategies.
J Med Econ 2007;10:119–34.
0. Freeman RV, O’Donnell M, Share D, et al. Nephropathy requiring
dialysis after percutaneous coronary intervention and the critical role of
an adjusted contrast dose. Am J Cardiol 2002;90:1068–73.
1. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention
of contrast nephropathy: meta-analysis. Lancet 2003;362:598–603.
2. Martin-Paredero V, Dixon SM, Baker JD, et al. Risk of renal failure
after major angiography. Arch Surg 1983;118:1417–20.
3. Gomes AS, Baker JD, Martin-Paredero V, et al. Acute renal
dysfunction after major arteriography. AJR Am J Roentgenol
1985;145:1249–53.
4. Nikolsky E, Mehran R, Turcot DB, et al. Impact of chronic kidney
disease on prognosis of patients with diabetes mellitus treated with
percutaneous coronary intervention. Am J Cardiol 2004;94:300–5.
5. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal
toxicity of a nonionic radiographic contrast agent after cardiac cathe-
terization. A prospective trial. Ann Intern Med 1989;110:119–24.
6. K/DOQI clinical practice guidelines for chronic kidney disease:
evaluation, classification, and stratification. Am J Kidney Dis 2002;39
2 Suppl 1:S1–266.
7. Tippins RB, Torres WE, Baumgartner BR, et al. Are screening serum
creatinine levels necessary prior to outpatient CT examinations?
Radiology 2000;216:481–4.
8. Choyke PL, Cady J, DePollar SL, et al. Determination of serum
creatinine prior to iodinated contrast media: is it necessary in all
patients? Tech Urol 1998;4:65–9.
9. Olsen JC, Salomon B. Utility of the creatinine prior to intravenous
contrast studies in the emergency department. J Emerg Med 1996;14:
543–6.
0. Krumlovsky FA, Simon N, Santhanam S, et al. Acute renal failure.
Association with administration of radiographic contrast material.
JAMA 1978;239:125–7.
1. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for
prediction of contrast-induced nephropathy after percutaneous coro-
nary intervention: development and initial validation. J Am Coll
Cardiol 2004;44:1393–9.
44
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
7
7
7
7
7
1428 McCullough JACC Vol. 51, No. 15, 2008
Contrast-Induced AKI April 15, 2008:1419–282. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts
contrast-induced nephropathy after percutaneous coronary interven-
tions. Kidney Int 2005;6:706–13.
3. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of
high- and low- osmolality iodinated contrast media. Radiology 1993;
188:171–8.
4. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and
nonionic contrast media in 1196 patients: a randomized trial. The
Iohexol Cooperative study. Kidney Int 1995;47:254–61.
5. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in
high-risk patients undergoing angiography. N Engl J Med 2003;348:
491–9.
6. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in
renal impairment. Br J Radiol 1999;72:701–3.
7. McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of
the renal safety of isosmolar iodixanol compared with low-osmolar
contrast media. J Am Coll Cardiol 2006;48:692–9.
8. Solomon R. The role of osmolality in the incidence of contrast-
induced nephropathy: a systematic review of angiographic contrast
media in high risk patients. Kidney Int 2005;68:2256–63.
9. Clauss W, Dinger J, Meissner C. Renal tolerance of iotrolan 280—a
meta analysis of 14 double-blind studies. Eur Radiol 1995;5:S79–84.
0. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and
comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in
patients with renal insufficiency undergoing coronary angiography: the
RECOVER study: a randomized controlled trial. J Am Coll Cardiol
2006;48:924–30.
1. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced
nephropathy in patients with chronic kidney disease undergoing
computed tomography: a double-blind comparison of iodixanol and
iopamidol. Invest Radiol 2006;41:815–21.
2. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in
Renally Impaired Patients (CARE) study: a randomized double-blind
trial of contrast-induced nephropathy in patients with chronic kidney
disease. Circulation 2007;115:3189–96.
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007
guidelines for the management of patients with unstable angina/non–
ST-elevation myocardial infarction—executive summary: a report of
the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Writing Committee to Revise the
2002 Guidelines for the Management of Patients With Unstable
Angina/Non–ST-Elevation Myocardial Infarction). J Am Coll Car-
diol 2007;50:652–726.
4. Manske CL, Sprafka JM, Strony JT, et al. Contrast nephropathy in
azotemic diabetic patients undergoing coronary angiography. Am J
Med 1990;89:615–20.
5. Laskey WK, Jenkins C, Selzer F, et al., NHLBI Dynamic Registry
Investigators. Volume-to-creatinine clearance ratio: a pharmacoki-
netically based risk factor for prediction of early creatinine increase
after percutaneous coronary intervention. J Am Coll Cardiol
2007;50:584–90.
6. Campbell DR, Flemming BK, Mason WF, et al. A comparative study
of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral
angiography. Can Assoc Radiol J 1990;41:133–7.
7. Moore RD, Steinberg EP, Powe NR, et al. Nephrotoxicity of
high-osmolality versus low-osmolality contrast media: randomized
clinical trial. Radiology 1992;182:649–55.8. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast
media-associated nephropathy: randomized comparison of 2 hydration
regimens in 1620 patients undergoing coronary angioplasty. Arch
Intern Med 2002;162:329–36.
9. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-
induced nephropathy with sodium bicarbonate: a randomized con-
trolled trial. JAMA 2004;291:2328–34.
0. Brar S. A Randomized Controlled Trial for the Prevention of Contrast
Induced Nephropathy With Sodium Bicarbonate vs. Sodium Chloride
in Persons Undergoing Coronary Angiography (the MEENA Trial).
Paper presented at: 56th Annual Scientific Session of the American
College of Cardiology; March 24–27, 2007; New Orleans, Louisiana.
1. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective
randomized trial of prevention measures in patients at high risk for
contrast nephropathy: results of the P.R.I.N.C.E. study. J Am Coll
Cardiol 1999;33:403–11.
2. Taylor AJ, Hotchkiss D, Morse RW, et al. PREPARED: Preparation
for Angiography in Renal Dysfunction: a randomized trial of inpatient
vs outpatient hydration protocols for cardiac catheterization in mild-
to-moderate renal dysfunction. Chest 1998;114:1570–4.
3. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-
agent-induced nephropathy by hemofiltration. N Engl J Med 2003;
349:1333–40.
4. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two
hemofiltration protocols for prevention of contrast-induced nephrop-
athy in high-risk patients. Am J Med 2006;119:155–62.
5. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid
prevents contrast-mediated nephropathy in patients with renal dys-
function undergoing coronary angiography or intervention. Circula-
tion 2004;110:2837–42.
6. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and
contrast-induced nephropathy in primary angioplasty. N Engl J Med
2006;354:2773–82.
7. Briguori C, Airoldi F, D’Andrea D, et al. Renal insufficiency following
contrast media administration trial (REMEDIAL): a randomized
comparison of 3 preventive strategies. Circulation 2007;115:1211–7.
8. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces
contrast-induced nephropathy: an analysis of contemporary percuta-
neous interventions. Am J Med 2005;18:843–9.
9. Chello M, Barbato R, Patti G, Goffredo C, di Sciasco G, Covino E.
Prevention of postoperative acute renal failure by statin therapy in
patients undergoing cardiac surgery. J Am Coll Cardiol 2008. In press.
0. McCullough PA, Rocher LR. Statin therapy in renal disease: harmful
or protective. Curr Atheroscler Rep 2007;9:18–24.
1. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS,
Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal
function after percutaneous coronary interventions. Am J Nephrol
2006;26:287–92.
2. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated
lipocalin (NGAL) as a biomarker for acute renal injury after cardiac
surgery. Lancet 2005;365:1231–8.
3. Movahed MR, Wong J, Molloi S. Removal of iodine contrast from
coronary sinus in swine during coronary angiography. J Am Coll
Cardiol 2006;47:465–7.
4. Michishita I, Fujii Z. A novel contrast removal system from the
coronary sinus using an adsorbing column during coronary angiogra-
phy in a porcine model. J Am Coll Cardiol 2006;47:1866–70.
